We also documented a total of 429 drug shortages over the 12-month period from September 2010 to August 2011. 6 In response to this sustained shortage of drugs, we developed a website to support clinicians in their management of drug shortages (www.fridaypm.ca). In the past few years, Apotex (in 2009), 7 Teva (in 2011), 8 and other Canadian drug manufacturers have received warning letters from the US Food and Drug Administration (FDA) concerning deviations from US good manufacturing practices. More recently, in 2011, Novartis International AG (the parent company of Sandoz Canada) received a similar notice from the FDA. 9 In response, following an extensive internal analysis of the issues raised by the FDA, Sandoz sent a letter to customers on February 15, 2012, stating that the company had expanded the remediation actions already under way and that it had opted to discontinue certain injectable products and to temporarily suspend the production of others. 10 The impact of these actions was an acute shortage of numerous parenteral drug products in Canada.
In this context of sustained drug shortages involving various manufacturers, we explored and compared the current situation in Canada and France. On 4 consecutive Fridays in March 2012, we extracted data on the current number of drug shortages and the drug manufacturers involved from 2 key public websites, our own in Canada (www.fridaypm.ca) and one in France (www.ansm.sante.fr). We found a substantial difference between the 2 countries, with 7-8 times the number of shortages in Canada as in France (Table 1 ). The Canadian situation was very worrisome, with almost 200 common drug items in short supply, in contrast to fewer than 40 in France.
The high level of drug shortages has had a major impact on hospital pharmacists' workload and poses a serious risk to patient care. During the current crisis, hospital pharmacists, physicians, and other clinicians have expended considerable time and effort to identify alternative treatment options, according to patients' needs and the resources available to each particular hospital.
What could explain the magnitude of the difference in drug shortages between these 2 industrialized countries? Many causes of drug shortages have been identified, including shortages of raw materials, manufacturing issues, the legal environment, industry reorganization, the grey market for drugs, third-party reimbursement rules, and contractual practices. 11 More specifically, in 2002, France put in place a preventive notification procedure for potential drug shortages. In 2004, the country adopted legislative changes requiring drug manufacturers to provide notification of any potential and actual drug shortages. 12 Similar legislative changes are now being discussed in the United States. 13 Although we cannot say with certainty which factors explain the discrepancy between France and Canada, the preventive actions taken in France have likely contributed to keeping drug shortages in that country at a relatively low level.
SigmaSanté, a drug purchasing group in Quebec, has taken action by introducing contract clauses that require mandatory reporting of drug shortages by drug manufacturers. These clauses, which took effect on April 1, 2012, include the mandatory reporting of drug shortages on the CHU Sainte-Justine website (www.fridaypm.ca). Additionally, we believe that legislative changes should be adopted in Canada, not only to mandate the reporting of actual and potential drug shortages by Canadian drug manufacturers, but also to ensure that the manufacturing and distribution of critical drugs do not rely on a single-source manufacturer. The current shortage of Sandoz products has convinced physicians, pharmacists, and other stakeholders of the significance of the problem, in terms of both clinician workload and, more importantly, patient safety. Pharmacists and physicians should be kept aware of trends in drug shortages to enable them to appropriately manage drug use in the face of ongoing shortages. Comparisons of the current drug shortage situation in Canada with shortages in other countries should be carried out to identify optimal legislative and contractual changes that could be adopted in Canada.
Additional Thoughts on Drug Shortages
I applaud and support Vaillancourt's editorial on the topic of drug shortages in a recent issue of the Canadian Journal of Hospital Pharmacy. 1 The topic and the editorialist's comments resonated with my experience. Each year, I find myself stating that "this is worst year I've ever seen for back orders", only to have an even worse situation arise the following year.
I absolutely agree that a new model of "strategic sourcing" must be undertaken, whereby the contract for drug supply is split between 2 or more vendors. Although this approach is not needed for all contracts, it should certainly be applied for critical medications. As pharmacists, we have a leadership role in advocating for this type of model with our purchasing groups or senior hospital administrators. The alternative, in the event of a shortage, is that patient care may be compromised. In addition, there is a human resource cost associated with trying to find alternative sources. Finally, even if an alternative can be found, it is often more expensive. In addition to Vaillancourt's vaccine example, the strategic sourcing model is also being used successfully by Canadian Blood Services for IV immunoglobulin and was previously used for plasma expanders.
Unfortunately, the process has been slow to gain acceptance among vendors, who anticipate reduced sales, and among hospitals, who anticipate increased acquisition costs. Although cost savings are important, focusing solely on the lowest acquisition cost can be short-sighted if continuity of supply is not maintained.
We should also be advocating for the concept of manufacturing redundancy. In other words, a company's manufacturing plants should have the ability to maintain some production of at least critical or single-source products if a failure occurs at the company's main production site. However, such redundancy is expensive, and most companies do not have this ability unless it is required. In fact, I know of only one company that has production redundancy built into its system. Finally, we should be advocating for the federal government, specifically Health Canada, to take a greater role in the prevention and monitoring of medication shortages. The Sandoz back-order situation has exposed many gaps in the exist-
